Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

From 9.1988 to 7.1989 we carried out on 50 patients at the Department of Gynaecology of the University of Freiburg a randomized double-blind study to compare the first dimeric, nonionic, hexaiodinated, water-soluble contrast agent (Iotrolan-300 corresponding to Isovist-300) with a nonionic, monomeric preparation (Iopamidol-300 corresponding to Solutrast-300) using the concentration of 300 mg I/ml. Both medicaments show a high contrast quality in the X-rays. Complications like hypersensitivity reactions resp. actual local irritations were not recorded. Iotrolan-300 was found to be the best tolerated of the two contrast media in respect of mildest intensity of pain.
 ...
PMID:[Iotrolan-300 versus Iopamidol-300 in hysterosalpingography]. 175 62

Iotrolan was used in concentrations of 240 and 300 mg I/ml for indirect lymphography in a total of 70 patients, and permitted a diagnostic evaluation of the peripheral lymphatics in all cases. The contrast quality was found to correlate with the concentration used. The concentration of 300 mg I/ml Iotrolan was judged to provide the better contrast density and definition. Side effects were limited to transient local erythema and pain during the infusion in one patient and a protracted reaction resembling serum sickness in another patient (Iotrolan 240 mg I/ml). Because of its excellent tolerance, Iotrolan is particularly suitable after subepidermal infusion for indirect lymphography, during which the local lymph drainage of cutaneous regions of interest can be evaluated.
 ...
PMID:Indirect lymphography with iotrolan. 256 90

The new isotonic contrast medium iotrolan has been compared with iopromide in aortofemoral arteriography, selective femoral arteriography, and intravenous digital substraction angiography (DSA). In each case a crossover study design has been chosen with special emphasis on patient comfort. Despite problems in the interpretation of results due to a "hangover" effect in selective peripheral arteriography, it may be concluded: (1) Iotrolan causes significantly less discomfort, such as the feeling of heat and most likely also pain, than iopromide. However, one patient reported slight pain after the injection of iotrolan even when no previous injection of iopromide had been performed; (2) in intravenous DSA contrast appeared 1 to 2 seconds later in the region of interest after the injection of iotrolan compared with iopromide, probably due to the slightly higher viscosity of the former agent; (3) otherwise, no differences between the two agents have been observed. No cardiovascular or other kind of side effects occurred with the exception of one slight allergy-like reaction in 60 patients.
 ...
PMID:Initial experience with a nonionic, dimeric contrast medium (iotrolan) in direct and indirect arteriography: a randomized, intraindividual double-blind study in 60 patients. 256 8

Arthrographic image quality and relative morbidity resulting from use of the nonionic dimer iotrolan and the ionic dimer ioxaglate sodium meglumine were compared in a prospective double-blind study performed in 80 patients. Radiographs obtained 2, 5, 10, 15, 20, and 25 minutes after injection of contrast agent were graded for diagnostic quality. Relative morbidity was evaluated by the physician during the examination and later by the patient by means of a questionnaire. Iotrolan demonstrated better image quality on serial radiographs in knee joints without previous effusions. Most differences were not significant. The mean duration of diagnostic-quality images for both contrast media was about 23 minutes. Iotrolan and ioxaglate caused equal postprocedural pain (in about 50% of patients). Other types of discomfort were less when iotrolan was used, but the differences were not significant. With regard to long-lasting image quality, both contrast media are suitable for arthrography.
 ...
PMID:Knee arthrography: comparison of iotrolan and ioxaglate sodium meglumine. 278 Oct 8